Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Pharmaceutical firm Eli Lilly invested $10m in US-based exosome drug developer Evox Therapeutics on Tuesday, supplying the capital through convertible bond financing alongside a $20m upfront payment as part of a research collaboration and licence deal. Evox had previously raised about $60m including $45.4m in a 2018 series B round led by Redmile Group and backed by GV, a subsidiary of internet and technology group Alphabet, as well as University of Oxford, existing backer Oxford Sciences Innovation, Panacea Healthcare…
